Piper Sandler downgraded Boston Properties from Overweight to Neutral and set a $64 price target, about 8.1% above its current share price. Boston Properties sold a 10.6% equity stake in its $2 billion 343 Madison Avenue office tower development in Midtown Manhattan to AVRS Partners. The 46-story tower, expected to be completed in 2029, has secured leases for about half of its 930,000 square feet at $200 per square foot, providing committed tenants before completion. The sale price of the stake was not disclosed, and the project is funded by a $1.2 billion construction loan.
The update on Boston Properties and its 343 Madison Avenue development is offered here with Pluang's Real Estate sector data for context. For readers following this sector, as of Oct 19, 2026 19:42 WIB, 15 of 47 US Real Estate stocks on Pluang rose while 20 fell. Essex Property Trust (ESS) traded at USD 267.74 with a slight decline of 0.63%, contrasting with CareTrust REIT (CTRE) which gained 0.60% to USD 36.77, and Welltower Inc. (WELL) which dropped 0.57% to USD 233.50, with typical hold times ranging from 4 to 112 days on Pluang.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
